A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors.

Trial Profile

A Phase 1 Study of AFP464 (Aminoflavone Prodrug) in Patients With Advanced Solid Tumors.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Dec 2013

At a glance

  • Drugs AFP 464 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 09 Apr 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 09 Nov 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Nov 2012 Planned number of patients changed from 75 to 60 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top